301393 昊帆生物
已收盘 12-31 15:00:00
资讯
新帖
简况
昊帆生物：公司将持续做好经营管理，为全体股东创造长期价值
证券日报 · 2025-12-22
昊帆生物：公司将持续做好经营管理，为全体股东创造长期价值
昊帆生物：淮安基地一期规划年产5130吨多肽合成试剂
证券之星 · 2025-12-10
昊帆生物：淮安基地一期规划年产5130吨多肽合成试剂
昊帆生物：公司经营受多因素影响
证券之星 · 2025-12-10
昊帆生物：公司经营受多因素影响
昊帆生物：公司账面资金主要用于生产基地建设、日常经营周转、研发投入等
证券之星 · 2025-11-27
昊帆生物：公司账面资金主要用于生产基地建设、日常经营周转、研发投入等
昊帆生物（301393）发布证券投资、期货及衍生品交易管理制度，11月21日股价下跌3.58%
证券之星 · 2025-11-21
昊帆生物（301393）发布证券投资、期货及衍生品交易管理制度，11月21日股价下跌3.58%
昊帆生物：2025年7月将标的公司纳入合并报表
证券之星 · 2025-11-18
昊帆生物：2025年7月将标的公司纳入合并报表
昊帆生物：安徽二期项目2025年1月正式生产
证券之星 · 2025-11-18
昊帆生物：安徽二期项目2025年1月正式生产
昊帆生物（301393）披露2025年中期权益分派实施公告，11月03日股价下跌2.74%
证券之星 · 2025-11-03
昊帆生物（301393）披露2025年中期权益分派实施公告，11月03日股价下跌2.74%
昊帆生物（301393）2025年三季报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 2025-10-30
昊帆生物（301393）2025年三季报简析：营收净利润同比双双增长，应收账款上升
昊帆生物（301393）披露公司2025年中期现金分红方案，10月29日股价上涨5.06%
证券之星 · 2025-10-29
昊帆生物（301393）披露公司2025年中期现金分红方案，10月29日股价上涨5.06%
图解昊帆生物三季报：第三季度单季净利润同比下降23.50%
证券之星 · 2025-10-28
图解昊帆生物三季报：第三季度单季净利润同比下降23.50%
昊帆生物(301393)9月30日股东户数1万户，较上期减少12.14%
证券之星 · 2025-10-28
昊帆生物(301393)9月30日股东户数1万户，较上期减少12.14%
10月27日昊帆生物发生1笔大宗交易 成交金额751.55万元
证券之星 · 2025-10-27
10月27日昊帆生物发生1笔大宗交易 成交金额751.55万元
10月20日昊帆生物发生1笔大宗交易 成交金额686.59万元
证券之星 · 2025-10-20
10月20日昊帆生物发生1笔大宗交易 成交金额686.59万元
昊帆生物：公司主营多肽合成试剂和分子砌块
证券之星 · 2025-09-17
昊帆生物：公司主营多肽合成试剂和分子砌块
9月15日昊帆生物涨9.10%，银河新动能混合A基金重仓该股
证券之星 · 2025-09-15
9月15日昊帆生物涨9.10%，银河新动能混合A基金重仓该股
昊帆生物（301393）2025年中报简析：营收净利润同比双双增长
证券之星 · 2025-08-30
昊帆生物（301393）2025年中报简析：营收净利润同比双双增长
昊帆生物：2025年上半年净利润同比增长15.31%
金融界 · 2025-08-28
昊帆生物：2025年上半年净利润同比增长15.31%
昊帆生物：公司2025年中报将于8月29日披露
证券之星 · 2025-08-05
昊帆生物：公司2025年中报将于8月29日披露
昊帆生物股价小幅回落 世卫组织将发布GLP-1减肥新指南
金融界 · 2025-07-23
昊帆生物股价小幅回落 世卫组织将发布GLP-1减肥新指南
加载更多
公司概况
公司名称：
苏州昊帆生物股份有限公司
所属行业：
化学原料和化学制品制造业
上市日期：
2023-07-12
主营业务：
苏州昊帆生物股份有限公司的主营业务是多肽合成试剂的研发、生产与销售。公司的主要产品是多肽合成试剂、通用型分子砌块、蛋白质试剂、脂质体与脂质纳米粒药用试剂。
发行价格：
67.68
{"stockData":{"symbol":"301393","market":"SZ","secType":"STK","nameCN":"昊帆生物","latestPrice":50.69,"timestamp":1767164592000,"preClose":51,"halted":0,"volume":340393,"delay":0,"changeRate":-0.0061,"floatShares":42104799,"shares":108000000,"eps":1.2682,"marketStatus":"已收盘","change":-0.31,"latestTime":"12-31 15:00:00","open":51.03,"high":51.3,"low":50.56,"amount":17303200,"amplitude":0.0145,"askPrice":50.78,"askSize":11,"bidPrice":50.69,"bidSize":43,"shortable":0,"etf":0,"ttmEps":1.2682,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":51,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":56.1,"lowLimit":45.9,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108000000,"isCdr":false,"pbRate":2.34,"roa":"--","peRate":39.970036,"roe":"4.3%","epsLYR":1.25,"committee":0.228758,"marketValue":5475000000,"turnoverRate":0.0081,"status":1,"floatMarketCap":2134000000},"requestUrl":"/m/hq/s/301393","defaultTab":"news","newsList":[{"id":"2593481063","title":"昊帆生物：公司将持续做好经营管理，为全体股东创造长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481063","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593481063?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:40","pubTimestamp":1766400000,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月22日，昊帆生物在互动平台回答投资者提问时表示，股价会受到二级市场多重因素影响，请理性看待短期股价波动。公司将持续做好经营管理，为全体股东创造长期价值。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-22/doc-inhcsrpa9066672.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-22/doc-inhcsrpa9066672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2590758213","title":"昊帆生物：淮安基地一期规划年产5130吨多肽合成试剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2590758213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590758213?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:48","pubTimestamp":1765327693,"startTime":"0","endTime":"0","summary":"投资者提问：董秘你好，淮安昊帆生产基地建设项目，规划产品34 种，设计产能为每年 5,130 吨。昊帆生物回复：尊敬的投资者您好，根据项目备案通知书，淮安昊帆新建年产5130吨多肽合成试剂项目（一期）规划的生产规模为：年产缩合试剂2500吨、保护试剂800吨、绿色N氨基化试剂100吨、手性消旋抑制试剂400吨、蛋白质试剂20吨、缩合活化助剂600吨、核苷酸试剂400吨、多肽合成交联剂20吨、保护氨基酸290吨。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000005106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2590373008","title":"昊帆生物：公司经营受多因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590373008?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:46","pubTimestamp":1765327572,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物(301393)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！司美格鲁肽核心专利将于明年三月份到期，对公司经营是否会有积极影响？昊帆生物回复：尊敬的投资者您好，公司主要产品为多肽合成试剂、通用型分子砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波动、行业竞争、产能布局等多方面因素影响，请投资者注意相关风险，理性判断。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000005083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2586472240","title":"昊帆生物：公司账面资金主要用于生产基地建设、日常经营周转、研发投入等","url":"https://stock-news.laohu8.com/highlight/detail?id=2586472240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586472240?lang=zh_cn&edition=full","pubTime":"2025-11-27 20:51","pubTimestamp":1764247892,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物11月26日在投资者关系平台上答复投资者关心的问题。公司账面资金主要用于生产基地建设、日常经营周转、研发投入等，部分暂时闲置资金依据相关规定进行现金管理。并购需综合考量标的行业契合度、估值合理性、协同效应及风险可控性等因素。公司始终坚持审慎原则，聚焦主业实现高质量发展，若有合适并购机会，将严格按照监管要求及时履行信息披露义务。感谢您的关注与建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700035534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2585314902","title":"昊帆生物（301393）发布证券投资、期货及衍生品交易管理制度，11月21日股价下跌3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585314902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585314902?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:42","pubTimestamp":1763736178,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，昊帆生物报收于49.85元，较前一交易日下跌3.58%，最新总市值为53.84亿元。该股当日开盘51.2元，最高51.92元，最低49.0元，成交额达7271.27万元，换手率为3.45%。近日，昊帆生物发布公告，公司制定《证券投资、期货及衍生品交易管理制度》，明确公司证券投资、期货及衍生品交易的行为规范。制度自董事会审议通过之日起实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK0229","301393"],"gpt_icon":0},{"id":"2584394607","title":"昊帆生物：2025年7月将标的公司纳入合并报表","url":"https://stock-news.laohu8.com/highlight/detail?id=2584394607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584394607?lang=zh_cn&edition=full","pubTime":"2025-11-18 11:33","pubTimestamp":1763436806,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物(301393)11月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司收购福斯特后，是否已经利用了他的产能进行生产？福斯特业绩什么时候合并报表？昊帆生物回复：尊敬的投资者，您好。公司于 2025 年7月将该标的公司纳入公司合并报表范围。相关信息烦请关注公司披露的定期报告和临时公告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800014227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2584073166","title":"昊帆生物：安徽二期项目2025年1月正式生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2584073166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584073166?lang=zh_cn&edition=full","pubTime":"2025-11-18 11:33","pubTimestamp":1763436806,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物11月17日在投资者关系平台上答复投资者关心的问题。安徽二期项目于2024年2月开始试生产，并于2025年1月开始正式生产。经历试生产后，2025年一季度和二季度产能相对稳定。公司目前的产能仍然处于相对紧张的状态，正在积极推进淮安昊帆生产基地的建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800014228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2580212584","title":"昊帆生物（301393）披露2025年中期权益分派实施公告，11月03日股价下跌2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580212584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580212584?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:54","pubTimestamp":1762181663,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，昊帆生物报收于55.43元，较前一交易日下跌2.74%，最新总市值为59.86亿元。公司近日发布公告，披露2025年中期权益分派实施方案。股权登记日为2025年11月10日，除权除息日为2025年11月11日。分红对象为截至股权登记日在中国结算深圳分公司登记在册的全体股东。本次权益分派后，相关股东承诺的最低减持价格及2024年限制性股票激励计划授予价格将相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300036461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2579415817","title":"昊帆生物（301393）2025年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579415817","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579415817?lang=zh_cn&edition=full","pubTime":"2025-10-30 06:43","pubTimestamp":1761777812,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期昊帆生物发布2025年三季报。截至本报告期末，公司营业总收入4.35亿元，同比上升32.47%，归母净利润9923.83万元，同比上升3.01%。按单季度数据看，第三季度营业总收入1.64亿元，同比上升59.45%，第三季度归母净利润2335.35万元，同比下降23.5%。本报告期昊帆生物应收账款上升，应收账款同比增幅达45.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000007155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393"],"gpt_icon":0},{"id":"2579736909","title":"昊帆生物（301393）披露公司2025年中期现金分红方案，10月29日股价上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579736909","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579736909?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:46","pubTimestamp":1761731208,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，昊帆生物报收于54.59元，较前一交易日上涨5.06%，最新总市值为58.96亿元。近日，苏州昊帆生物股份有限公司发布公告，披露2025年中期现金分红方案。根据公告内容，公司拟以扣除回购专用账户股份后的总股本107,181,852股为基数，向全体股东每10股派发现金股利1.35元（含税），预计分红总额14,469,550.02元，不送红股，不进行资本公积金转增股本。若在股权登记日前公司总股本发生变动，将维持分配比例不变，相应调整分配总额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900037410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2578953125","title":"图解昊帆生物三季报：第三季度单季净利润同比下降23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578953125","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578953125?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:20","pubTimestamp":1761650418,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物2025年三季报显示，公司主营收入4.35亿元，同比上升32.47%；归母净利润9923.83万元，同比上升3.01%；扣非净利润8127.2万元，同比下降2.79%；其中2025年第三季度，公司单季度主营收入1.64亿元，同比上升59.45%；单季度归母净利润2335.35万元，同比下降23.5%；单季度扣非净利润1927.16万元，同比下降20.76%；负债率7.86%，投资收益1260.95万元，财务费用-819.54万元，毛利率38.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800035867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393"],"gpt_icon":0},{"id":"2578931367","title":"昊帆生物(301393)9月30日股东户数1万户，较上期减少12.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578931367","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578931367?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:46","pubTimestamp":1761644777,"startTime":"0","endTime":"0","summary":"证券之星消息，近日昊帆生物披露，截至2025年9月30日公司股东户数为1.0万户，较6月30日减少1385.0户，减幅为12.14%。在生物制品行业个股中，昊帆生物股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年6月30日至2025年9月30日，昊帆生物区间跌幅为3.12%，在此期间股东户数减少1385.0户，减幅为12.14%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800032687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2578153216","title":"10月27日昊帆生物发生1笔大宗交易 成交金额751.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578153216","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578153216?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:53","pubTimestamp":1761555225,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日昊帆生物发生大宗交易，交易数据如下：大宗交易成交价格47.06元，相对当日收盘价折价9.64%，成交15.97万股，成交金额751.55万元，买方营业部为银泰证券有限责任公司上海长宁区延安西路证券营业部，卖方营业部为东方证券股份有限公司上海徐汇广元西路证券营业部。近三个月该股共发生2笔大宗交易，合计成交3078.0手，折价成交2笔。截至2025年10月27日收盘，昊帆生物报收于52.08元，上涨1.56%，换手率3.88%，成交量1.63万手，成交额8544.34万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700022047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2576800834","title":"10月20日昊帆生物发生1笔大宗交易 成交金额686.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576800834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576800834?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:57","pubTimestamp":1760950644,"startTime":"0","endTime":"0","summary":"证券之星消息，10月20日昊帆生物发生大宗交易，交易数据如下：大宗交易成交价格46.36元，相对当日收盘价折价9.31%，成交14.81万股，成交金额686.59万元，买方营业部为银泰证券有限责任公司上海长宁区延安西路证券营业部，卖方营业部为东方证券股份有限公司上海徐汇广元西路证券营业部。近三个月该股共发生1笔大宗交易，合计成交1481.0手，折价成交1笔。截至2025年10月20日收盘，昊帆生物报收于51.12元，上涨1.65%，换手率1.64%，成交量6921.0手，成交额3520.18万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000020698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2568468258","title":"昊帆生物：公司主营多肽合成试剂和分子砌块","url":"https://stock-news.laohu8.com/highlight/detail?id=2568468258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568468258?lang=zh_cn&edition=full","pubTime":"2025-09-17 15:18","pubTimestamp":1758093495,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物09月17日在投资者关系平台上答复投资者关心的问题。公司主营产品为多肽合成试剂、分子砌块等特色化学试剂，上述产品不属于原料药。公司始终坚持以市场需求为导向，不断优化产品结构，提高产品质量，提升核心竞争力，公司将通过提升经营业绩、加强信息披露等多种方式积极维护公司价值。若有重大事项，公司将及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700021827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2567194133","title":"9月15日昊帆生物涨9.10%，银河新动能混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2567194133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567194133?lang=zh_cn&edition=full","pubTime":"2025-09-15 16:29","pubTimestamp":1757924984,"startTime":"0","endTime":"0","summary":"证券之星消息，9月15日昊帆生物涨9.10%，收盘报59.2元，换手率17.04%，成交量7.18万手，成交额4.18亿元。重仓昊帆生物的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河新动能混合A。该公募基金现任基金经理为鲍武斌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500020648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2563088390","title":"昊帆生物（301393）2025年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2563088390","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563088390?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:37","pubTimestamp":1756507054,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期昊帆生物发布2025年中报。根据财报显示，昊帆生物营收净利润同比双双增长。截至本报告期末，公司营业总收入2.7亿元，同比上升20.1%，归母净利润7588.48万元，同比上升15.31%。持有昊帆生物最多的基金为银河新动能混合A，目前规模为1.77亿元，最新净值2.0134，较上一交易日上涨0.16%，近一年上涨64.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000012300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393"],"gpt_icon":0},{"id":"2562081677","title":"昊帆生物：2025年上半年净利润同比增长15.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562081677","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562081677?lang=zh_cn&edition=full","pubTime":"2025-08-28 16:59","pubTimestamp":1756371544,"startTime":"0","endTime":"0","summary":"昊帆生物公告，2025年上半年营业收入2.7亿元，同比增长20.10%。归属于上市公司股东的净利润7588.48万元，同比增长15.31%。公司计划不派发现金红利，不送红股，不以公积金转增股本。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/28165952776666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301393"],"gpt_icon":0},{"id":"2557636973","title":"昊帆生物：公司2025年中报将于8月29日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2557636973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557636973?lang=zh_cn&edition=full","pubTime":"2025-08-05 16:54","pubTimestamp":1754384056,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物(301393)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司今年中报预估利润多少昊帆生物回复：尊敬的投资者您好，公司2025年中报将于8月29日披露，请您关注届时发布的定期报告，谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500027918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2553525742","title":"昊帆生物股价小幅回落 世卫组织将发布GLP-1减肥新指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2553525742","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553525742?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:24","pubTimestamp":1753201441,"startTime":"0","endTime":"0","summary":"截至2025年7月22日15时，昊帆生物股价报55.37元，较前一交易日下跌0.74%。当日成交量为28927手，成交金额达1.61亿元。昊帆生物所属板块包括生物制品、CRO等领域。世界卫生组织计划于2025年9月发布基于GLP-1疗法的成人肥胖症治疗新指南。该指南将明确GLP-1受体激动剂的临床应用标准，标志着世卫组织首次正式推荐使用减肥药物治疗肥胖症。在相关产业链中，昊帆生物被列为值得关注的企业之一。2025年7月22日，昊帆生物主力资金净流入74.15万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/23002451904873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4144","BK0229","GLP","301393","BK4590"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767553455439,"stockEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0117},{"period":"3month","weight":-0.0207},{"period":"6month","weight":-0.0498},{"period":"1year","weight":0.2795},{"period":"ytd","weight":0.2795}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州昊帆生物股份有限公司","boardCode":"AI0026","boardName":"化学原料和化学制品制造业","stockholders":"10024人(较上一季度减少12.14%)","perCapita":"4200股","listingDate":"2023-07-12","address":"江苏省苏州市虎丘区高新区长亭路1号","registeredCapital":"10800万元","survey":" 苏州昊帆生物股份有限公司的主营业务是多肽合成试剂的研发、生产与销售。公司的主要产品是多肽合成试剂、通用型分子砌块、蛋白质试剂、脂质体与脂质纳米粒药用试剂。","listedPrice":67.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昊帆生物,301393,昊帆生物股票,昊帆生物股票老虎,昊帆生物股票老虎国际,昊帆生物行情,昊帆生物股票行情,昊帆生物股价,昊帆生物股市,昊帆生物股票价格,昊帆生物股票交易,昊帆生物股票购买,昊帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}